Efficacy and Safety Results of the Afatinib Expanded Access Program

INTRODUCTION: Afatinib is an oral, irreversible ErbB family blocker approved for first-line treatment of metastatic epidermal growth factor receptor (EGFR) mutation–positive non–small cell lung cancer (NSCLC). The expanded access program (EAP) allowed early access to afatinib and provided additional...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Edward S., Halmos, Balazs, Kohut, Ingrid F., Patel, Taral, Rostorfer, Regan D., Spira, Alexander I., Cseh, Agnieszka, McKay, John, Wallenstein, Gudrun, Mileham, Kathryn F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488108/
https://www.ncbi.nlm.nih.gov/pubmed/28680960
http://dx.doi.org/10.1007/s40487-017-0043-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488108/
https://www.ncbi.nlm.nih.gov/pubmed/28680960
http://dx.doi.org/10.1007/s40487-017-0043-5

Ejemplares similares